BiotechTube

Test Product + Reference Product + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchial Asthma

Conditions

Bronchial Asthma

Trial Timeline

Mar 12, 2019 → Dec 20, 2019

NCT ID
NCT04051710

About Test Product + Reference Product + Placebo

Test Product + Reference Product + Placebo is a phase 3 stage product being developed by Aurobindo Pharma for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT04051710. Target conditions include Bronchial Asthma.

What happened to similar drugs?

3 of 15 similar drugs in Bronchial Asthma were approved

Approved (3) Terminated (3) Active (9)
✅MontelukastMerckApproved
✅Formoterol fumerate + fenoterol/ipratropium bromideNovartisApproved
✅Montelukast chewable tablets + Budesonide inhaler + Placebo to montelukast chewable tablets + Placebo to budesonide inhalerOrganonApproved
🔄Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
🔄90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
🔄Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
❌Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04051710Phase 3Completed

Competing Products

20 competing products in Bronchial Asthma

See all competitors
ProductCompanyStageHype Score
TacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 2
35
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
40
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
40
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
40
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3
32
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerGlenmark PharmaceuticalsPhase 3
36
Symbicort Turbuhaler + Symbicort pMDI + Pulmicort TurbuhalerAstraZenecaPhase 3
40
RoflumilastAstraZenecaPhase 3
40
RoflumilastAstraZenecaPhase 2/3
38
Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatmentAstraZenecaPhase 3
32
CiclesonideAstraZenecaPhase 3
40
Montelukast plus prednisolone + PrednisoloneMerckPhase 2
35
MontelukastMerckApproved
43
Formoterol fumerate + fenoterol/ipratropium bromideNovartisApproved
43
inhaled corticosteroid therapyNovartisPhase 1/2
32
PF-00610355 + PF - 00610355 + PF - 00610355PfizerPhase 2
27
NivolumabBristol Myers SquibbPhase 2
39
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
42
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
42